Cellular and molecular biology of small cell lung cancer: an overview

被引：76

作者：

Karachaliou, Niki ^{[1
]}

Pilotto, Sara ^{[2
]}

Lazzari, Chiara ^{[3
]}

Bria, Emilio ^{[2
]}

de Marinis, Filippo ^{[3
]}

Rosell, Rafael ^{[1
,4
,5
,6
,7
]}

机构：

[1] Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell, Barcelona, Spain

[2] Univ Verona, Azienda Osped Univ Integrata, Dept Med Oncol, I-37100 Verona, Italy

[3] European Inst Oncol IEO, Div Thorac Oncol, Milan, Italy

[4] Pangaea Biotech, Barcelona, Spain

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[6] Mol Oncol Res MORe Fdn, Barcelona, Spain

[7] Germans Trias & Pujol Hlth Sci Inst & Hosp, Campus Can Ruti, Badalona, Spain

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 01期

关键词：

Small cell lung cancer (SCLC); targeted therapies; biomarkers; immune system; ACHAETE-SCUTE HOMOLOG-1; FIBROBLAST-GROWTH-FACTOR; STEM-CELLS; NEUROENDOCRINE TUMORS; THERAPEUTIC TARGET; MUTATIONAL LANDSCAPE; PROGNOSTIC-FACTOR; PHASE-II; EXPRESSION; CARCINOMA;

D O I：

10.3978/j.issn.2218-6751.2016.01.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating disease to research and treat. Numerous attempts to enhance the anti-tumor effects of traditional chemotherapy for SCLC have not been successful. For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that, when combined, render it a malignant neoplasm. New and novel therapies based on understanding these mechanisms of transformation are needed. Herein we provide an in-depth view of some of the genomic alterations in SCLC that have emerged as potential targets for therapeutic intervention.

引用

页码：2 / 15

页数：14

共 126 条

[41] Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis [J].

Hiroshima, Kenzo ;

Iyoda, Akira ;

Shida, Takashi ;

Shibuya, Kiyoshi ;

Iizasa, Toshihiko ;

Kishi, Hirohisa ;

Tanizawa, Tohru ;

Fujisawa, Takehiko ;

Nakatani, Yukio .

MODERN PATHOLOGY, 2006, 19 (10) :1358-1368

[42] Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium [J].

Hong, KU ;

Reynolds, SD ;

Watkins, S ;

Fuchs, E ;

Stripp, BR .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (02) :577-588

[43] EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation [J].

Hubaux, Roland ;

Thu, Kelsie L. ;

Coe, Bradley P. ;

MacAulay, Calum ;

Lam, Stephen ;

Lam, Wan L. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) :1102-1106

[44]

IKEGAKI N, 1994, CANCER RES, V54, P6

[45] Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer [J].

Ishii, Hidenobu ;

Azuma, Koichi ;

Kawahara, Akihiko ;

Yamada, Kazuhiko ;

Imamura, Yohei ;

Tokito, Takaaki ;

Kinoshita, Takashi ;

Kage, Masayoshi ;

Hoshino, Tomoaki .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) :426-430

[46]

ISHIZAKA Y, 1989, ONCOGENE, V4, P1519

[47]

Ito T, 2000, DEVELOPMENT, V127, P3913

[48] CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis [J].

Jaiswal, Siddhartha ;

Jamieson, Catriona H. M. ;

Pang, Wendy W. ;

Park, Christopher Y. ;

Chao, Mark P. ;

Majeti, Ravindra ;

Traver, David ;

van Rooijen, Nico ;

Weissman, Irving L. .

CELL, 2009, 138 (02) :271-285

[49] Targeting the neural cell adhesion molecule in cancer [J].

Jensen, Markus ;

Berthold, Frank .

CANCER LETTERS, 2007, 258 (01) :9-21

[50] EXPRESSION OF BCL-2 ONCOGENE PROTEIN IS PREVALENT IN SMALL-CELL LUNG CARCINOMAS [J].

JIANG, SX ;

SATO, YC ;

KUWAO, S ;

KAMEYA, T .

JOURNAL OF PATHOLOGY, 1995, 177 (02) :135-138

← 1 2 3 4 5 6 7 8 9 10 →